Investigational cannabinoids in seizure disorders, what have we learned thus far?
Autor: | Slobodan M. Jankovic, Ziyad Tantoush, Marko Folić, Milan Radovanovic, Dejana Ružić Zečević, Goran Babic |
---|---|
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Drug Resistant Epilepsy Cannabidivarin medicine.medical_treatment MEDLINE Epilepsies Myoclonic Bioinformatics 03 medical and health sciences Epilepsy 0302 clinical medicine Dravet syndrome medicine Animals Humans Pharmacology (medical) Pharmacology Cannabinoids Lennox Gastaut Syndrome business.industry Drugs Investigational General Medicine medicine.disease Clinical trial 030104 developmental biology Anticonvulsant Drug Design Anticonvulsants business Cannabidiol 030217 neurology & neurosurgery medicine.drug Lennox–Gastaut syndrome |
Zdroj: | Expert Opinion on Investigational Drugs. 27:535-541 |
ISSN: | 1744-7658 1354-3784 |
DOI: | 10.1080/13543784.2018.1482275 |
Popis: | The anticonvulsant activity of cannabinoids attracted much attention in the last decade. Cannabinoids that are currently investigated with the intention of making them drugs for the treatment of epilepsy are cannabidiol, cannabidivarin, Δ9-tetrahydrocannabivarin, and Δ9-tetrahydrocannabinolic acid.In this review, the authors look at the results of preclinical and clinical studies with investigational cannabinoids. Relevant literature was searched for in MEDLINE, SCOPUS, EBSCO, GOOGLE SCHOLAR, and SCINDEX databases.Preclinical studies confirmed anticonvulsant activity of cannabidiol and cannabidivarin in a variety of epilepsy models. While the results of clinical trials with cannabidivarin are still awaited, cannabidiol showed clear therapeutic benefit and good safety in patients with therapy-resistant seizures associated with Dravet syndrome and in patients with Lennox-Gastaut syndrome who have drop seizures. However, the full therapeutic potential of cannabinoids in treatment-resistant epilepsy needs to be investigated in the near future. |
Databáze: | OpenAIRE |
Externí odkaz: |